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1. Introduction
The first spinal anesthesia was carried out by Dr August Bier in 1899 and his anesthetic
technique has become the standard practice for lower extremity and abdominal surgery
worldwide [1]. Nowadays, the most commonly used drugs for spinal anesthesia are local
anesthetics. However, a major disadvantage of single injection spinal anesthesia is its limited
duration of action. In clinical practice, a number of adjuvants have been added to intrathecal
local anesthetics for supplementation of intraoperative anesthesia and postoperative analge‐
sia. They have advantages as they reduce the dose of local anesthetic; provide long lasting
postoperative analgesia with reduced incidence of central nervous system depression, motor
effects or hypotension [2].
Midazolam, synthesized by Walsar and colleagues in 1976, was the first clinically used water
soluble benzodiazepine [3]. It is also the first benzodiazepine that was produced primarily for
use in anesthesia [4]. In 1986, Faull and Villiger demonstrated that there is a high density of
benzodiazepine (GABA‐A) receptors in lamina II of the dorsal horn in the human spinal cord,
suggesting a possible role in pain modulation [5]. One year later, Goodchild and Serrao
reported that benzodiazepines might have analgesic effects at the spinal cord level in animals
[6]. In 1990s, analgesic efficacy of intrathecal midazolam in humans has been demonstrated
[7-9]. Naltrindole, a δ-selective opioid antagonistic agent, suppresses the antinociceptive effect
of intrathecal midazolam, suggesting that intrathecal midazolam is involved in the release of
an endogenous opioid acting at spinal δ receptors [10].
This chapter is going to focus on the relationship between midazolam and spinal anesthesia.
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2. Midazolam
Benzodiazepines commonly used in the perioperative period include diazepam, midazolam,
and lorazepam, as well as the selective benzodiazepine antagonist flumazenil (Figure 1). The
chemical structure of the benzodiazepines contains a benzene ring fused to a seven-member
diazepine ring, hence their name. They are all composed of a benzene ring (A) fused to a seven-
membered 1, 4-diazepine ring (B). Anesthesiologically relevant benzodiazepine agonists also
contain a 5-aryl substituent (ring C), which enhances the pharmacological potency. However,
the benzodiazepine antagonist flumazenil has two important structural differences as com‐
pared to the above agonists. Flumazenil has a keto function at position 5 instead of ring C, and
a methyl substituent at position 4. Hence benzodiazepines are unique among the group of
intravenous anesthetics in that their action can readily be terminated by administration of their
selective antagonist flumazenil [11, 12].
Figure 1. Chemical structure of the three commonly used benzodiazepines and their antogonist flumazenil.
Midazolam is an imidazobenzodiazepine. This results in the ability of a water molecule to open
the diazepine ring, thus encouraging aqueous solubility. The equilibrium between the two
forms of midazolam is determined by pH. The change from one form to the other is relatively
slow, having a half-life of 10 minutes. The pH in the ampoule containing midazolam hydro‐
chloride is 3.0 and so the ring is open and it is soluble. Once subjected to body pH 7.4, the
diazepine ring closes and the midazolam becomes lipid-soluble, allowing it readily to cross
the blood–brain barrier. In the plasma most of the midazolam (95%) is protein-bound. Small
changes in its plasma protein binding will produce large changes in the amount of free drug
available, which may have consequences in clinical practice [13]. The high lipophilicity of
midazolam accounts for the relatively large volume of distribution at steady-state [14]. Older
age does not increase the volume of distribution significantly [15, 16]. However, in obese
patients, the volume of distribution is increased and the elimination half-time is prolonged
while the clearance remains unchanged [15].
Elimination half-time is independent of the route of administration. Major operations seem to
increase the volume of distribution and prolong the elimination half-time [16]. Following
intravenous administration, midazolam is rapidly distributed and the distribution half-time
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is 6-15 min [17]. The fused imidazole ring of midazolam is oxidized much more rapidly than
the methylene group of the diazepine ring of other benzodiazepines [18-20]. In elderly men,
the clearance of midazolam is reduced and the elimination half-time is prolonged as compared
to young males. Between elderly and young women, however, no significant differences were
detected in the clearance or the elimination halftime of midazolam [15]. In addition to the liver,
midazolam is also metabolized at extrahepatic sites. This has been demonstrated by the
discovery of metabolites following intravenous injection of midazolam during the anhepatic
period of liver transplantation [21]. In patients with advanced cirrhosis of the liver, the plasma
clearance is reduced and the elimination half-time is prolonged as compared to healthy
volunteers, while the volume of distribution remains unchanged [22].
The first step in the metabolism of midazolam is hydroxylation [23]. The two metabolites
formed are α-hydroxymidazolam and 4-hydroxymidazolam, both are pharmacologically
active [14, 24]. The α-hydroxymidazolam is as potent as the parent compound and may
contribute significantly to the effects of the parent drug when present in sufficiently high
concentrations. 4-Hydroxymidazolam is quantitatively unimportant [25]. Both metabolites are
rapidly conjugated by glucuronic acid to form products which have been considered to be
pharmacologically inactive [14]. On the other hand; glucuronidated α-hydroxymidazolam, the
main metabolite of midazolam, has a substantial pharmacological effect and can penetrate the
intact blood–brain barrier. The elimination half-time of α-hydroxymidazolam is about 70 min
[25]. However, it can accumulate in patients with renal failure. Furthermore, in vitro binding
studies show that the affinity of glucuronidated α-hydroxymidazolam to the cerebral benzo‐
diazepine receptor is only about ten times weaker than that of midazolam or unconjugated
α-hydroxymidazolam [26].
Midazolam is supplied as hydrochloride salt with a pH less than 4.0 (buffered to an acidic pH of
3.5). This is important because midazolam displays pH-dependent solubility. The diazepine
ring of midazolam accounts for its stability in solution and rapid metabolism. It remains open
at pH value of <4, thus maintaining drug´s water solubility. The ring closes at pH value of >
4, as when the drug is exposed to physiologic pH, thus converting midazolam to a highly lipid
soluble drug [27] and this lipophilicity is responsible for its rapid CNS effect and large volume
of distribution [28]. Therefore the pH of the commercial midazolam hydrochloride preparation
is adjusted to 3 with hydrochloride acid and sodium hydroxide. As midazolam is injected into
patients, pH is increased and the ring is closed thus increasing the lipid solubility.
Midazolam exerts its effect by occupying benzodiazepine receptor that modulates γ-amino
butyric acid (GABA), the major inhibitory neurotransmitter in the brain. Benzodiazepine
receptors are found in the olfactory bulb, cerebral cortex, cerebellum, hippocampus, substantia
nigra, inferior colliculus, brain stem, and spinal cord. There are two types of GABA receptors;
benzodiazepine receptors are part of the benzodiazepine-GABAA-chloride channel receptor
complex. Benzodiazepine binding site is located on the γ2 subunit of the GABA receptor
complex [29, 30]. With the activation of the GABAA receptor, gating of the channel for chloride
ions is started after which the cell becomes hyperpolarised and resistant to neuronal excitation.
The hypnotic effects of benzodiazepine are mediated by alterations in the potential dependent
calcium ion flux [31]. Hypnotic, sedative, amnesic, and anticonvulsant effects are mediated by
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α1 GABA receptors and anxiolysis and centrally acting muscle relexant properties are
mediated by α2 GABA receptors [31].
The  anxiolytic  effect  of  midazolam  is  via  its  action  at  mammillary  body.  Presumably
midazolam exerts its anxiolytic property like other benzodiazepines by increasing glycine
inhibitory  neurotransmitter.  Midazolam  also  possesses  anticonvulsant  action  which  is
attributed to enhanced activity of GABA on the brain’s motor circuit. It exhibits a muscle
relaxant  effect  via  its  action  at  the  glycine  receptors  in  the  spinal  cord.  Midazolam
administered via intrathecal or epidural routes can produce analgesia, probably due to its
GABA mediated action [4]. Other mechanisms of action including its interaction with opiate
receptors have also been proposed [10].
3. Intrathecal midazolam: Useful or toxic?
Spinal anesthesia is the most commonly used regional anesthetic technique. Local anesthetic
agents used for this purpose provide good intraoperative analgesia. However, they provide a
very limited postoperative duration of action. In order to overcome this problem and to
maximise the duration of anesthesia-analgesia, many adjuvants, such as intrathecal opioids
and non-opioids, have increasingly been tried in the last two decades to relieve postoperative
pain [32-34]. Among the various methods availabe for providing post-operative analgesia, the
benefits of intrathecal opioids and non-opioids as adjuncts in spinal anaesthesia are well
documented. Unfortunately the addition of intrathecal opioids is associated with dose-related
adverse effects such as respiratory depression, nausea, vomiting, urinary retention, pruritus,
and sedation [35]. Therefore, the use of non-opioids such as ketamine, clonidine, neostigmine,
magnesium sulfate, and midazolam have become popular adjuncts for post-operative
analgesia. However, side-effects in the postoperative period render most adjuvants less than
ideal.
Midazolam, a water soluble benzodiazepine, has been used via intrathecal route in the
management of acute (perioperative) [36, 37], chronic [38] and cancer [39] pain. Goodchild and
Noble were the first to demonstrate the role of intrathecal midazolam in relieving pain of
somatic origin in humans [36]. The rationale for the use of intrathecal midazolam focuses on
the awareness that it is an agonist at the benzodiazepine binding site, a subunit of the pen‐
tameric gammaaminobutyric acid (GABA-A) receptor. Agonist occupancy of the benzodiaze‐
pine binding site enhances the activity of GABA at the GABA-A receptor. The GABA receptor
is a chloride ionophore that, when activated, typically stabilises the transmembrane potential
at, or near, the resting potential. In neurons, this typically serves to decrease excitability [40].
Intrathecal benzodiazepine-induced analgesia is spinally mediated. Binding sites are GABA
receptors, abundantly present in the dorsal root nerve cells, with the maximum concentration
found within lamina II of the dorsal nerve cells, a region that plays a prominent role in
processing nociceptive and thermoceptive stimulation [36]. The present cumulative experience
with intrathecal midazolam across species broadly confirms the safety thereof, the analgesic
activity of the molecule and its benzodiazepine pharmacology, and the lack of irreversible
effects [8].
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Intrathecal midazolam was originally shown to have antinociceptive properties in animals in
the early 1980s [41, 42]. And later in 1991, Malinovsky et al. demonstrated potential of
neurotoxic effect of intrathecal administration of ketamine and midazolam in rabbits [43].
Midazolam-treated rabbits showed significant changes in both blood-brain barrier and light
microscopy studies. They postulated that, the neurotoxicity might be due to the 10% HCL used
as a vehicle in the preparation of midazolam. In 1999 Erdine et al. conducted a study of
intrathecal midazolam in rabbits and reported neurotoxicity [44]. They concluded that the
neurotoxicity was due to the use of intrathecal catheter. They also reported that this toxic
change did not produce any change in the vital parameters of those animals. However, in 1991
Schoeffler et al. conducted a detailed histological study in rats following administration of
midazolam via subarachnoid catheter while investigating control of cancer pain [45]. They
found that the amount of fibrosis, infiltration, and deformation in midazolam group is not
different from saline control group. Aguilar et al. in 1994, conducted study and reported that
intrathecal midazolam can relieve pain in different clinical situations (as long as 13 months) and
they did not show any toxic neurological effects following prolonged administration of
intrathecal midazolam [46]. Nevetheless, in 1995 Svensson et al. conducted a morphological
study on rat spinal cords following chronic subarachnoid administration of midazolam,
documenting its neurotoxic effect [47].
In 1996, Valentine et al. studied the effect of intrathecal midazolam along with hyperbaric
bupivacaine for caesarean section delivery under spinal anaesthesia and found no side effects
attributable to midazolam [8]. In the same year, Borg and Krijnen reported long-term intra‐
thecal administration of midazolam and clonidine in patients with refractory musculoskeletal
pain persisting more than 2.5 years [9]. They administered intrathecal midazolam up to 6mg/
day which showed promising results, they also reported that this high dose did not cause any
neurological deficits in those patients suffering with chronic refractory musculoskeletal pain
[9]. One year later, Bozkurt et al. studied the histological change following epidural adminis‐
tration of midazolam in neonatal rabbits and showed a variable degree of neurotoxic effects
such as degeneration of vacuoles, cytoplasm and neurofilaments, disruption of myelin sheaths,
lysis of cell membranes, perivascular oedema, and pyknosis of nuclei [48]. The toxic effects of
acidic saline and midazolam (commercially available preparations) were similar. In the same year,
Bahar et al. examined in an animal model whether intrathecal midazolam, alone or with
fentanyl, can achieve anaesthesia sufficient for laparotomy, comparable to lidocaine; they
concluded that midazolam, when injected intrathecally, produces reversible, segmental,
spinally mediated antinociception, sufficient to provide balanced anaesthesia without any
adverse effect [49]. In 1999, Nishiyama et al. conducted histopathological study in cats with
intrathecal midazolam. Neither acute histological damage nor inflammatory reaction of the
spinal cord were seen in the cats [50].
In 1998, Nishiyama et al. studied the effect of continuous infusion of midazolam with local
anesthetic for treatment of postoperative pain and showed that adding midazolam to a
continuous epidural infusion of bupivacaine provides better analgesia, amnesia, and sedation
than bupivacaine alone without any side effects [51]. Also Nishiyama et al. in the same year
studied the effect of adding midazolam and bupivacaine to human cerebrospinal fluid in glass
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test tubes and the solution was examined for any change of pH and a reduction in the
transparency of the solution [52]. Cerebrospinal pH was decreased to below 7.0 adding more
than 3 mg of midazolam, more than 1.9 mL of 0.25% bupivacaine or 1.3 mL of the mixture.
Cerebrospinal transparency by adding more than 0.7 mg of midazolam, 1.1 mL of 0.25%
bupivacaine or 0.6 mL of the mixture. Midazolam in saline neither decreased the pH below
nor reduced transparency. These results are very important so this study showed that clinically
useful doses of intrathecal or epidural midazolam were not neurotoxic. In the same year, Gulec
et al. showed that caudal administration of a bupivacaine-midazolam mixture produces a
longer duration of postoperative analgesia than a bupivacaine-morphine mixture and
bupivacaine alone [53]. Batra et al. in 1999, conducted a study on postoperative analgesia in
patients undergoing knee arthroscopy following intrathecal administration of midazolam in
combination with hyperbaric bupivacaine [54]. They demonstrated that this combination
produces better postoperative analgesia. In 2001, Kim and Lee showed a dose-dependent effect
of intrathecal midazolam [55]. Sen et al. reported that intrathecal midazolam produced
significant postoperative pain relief together with antiemetic effect and tranquillity in patients
undergoing caesarean section delivery [56]. Maharjan et al showed that caudal administration
of midazolam-bupivacaine mixture significantly prolongs postoperative analgesia compared
to bupivacaine alone in children undergoing genitourinary surgery [57]. Moreover, other
studies have shown that addition of intrathecal midazolam significantly improves the duration
and quality of spinal anesthesia and provides prolonged perioperative analgesia without any
significant side effects and neurological damage [58-61]. Prochazka shared their decade long
experience of using intrathecal midazolam in 2006 [62]. According to them, intrathecal
midazolam is able to provide good analgesia in most patients and is a very suitable supplement
for postoperative and long-term analgesia without demand of expensive systems (Patient
Controlled Analgesia and other drug infusion systems, etc.). On the other hand, recent studies
showed that intrathecal midazolam appears to improve perioperative analgesia and it can be
useful and safe adjunct to bupivacaine for intrathecal analgesia during different surgical
operations [35, 63-66].
Yegin et al. in 2004, conducted a study on the analgesic and sedative effects of intrathecal 2mg
preservative free midazolam in perianal surgery under spinal anesthesia [37]. They found that
the addition of bupivacaine produces a more effective and longer analgesia with a mild
sedative effect in patients in the experimental group. One year later Agrawal et al. investigated
postoperative pain relief following intrathecal administration of 1mg preservative free
midazolam with bupivacaine in patients scheduled for elective lower abdominal, lower limb,
and endoscopic urological surgeries [67]. They showed that intrathecal midazolam and
bupivacaine provide longer duration of postoperative analgesia as compared to intrathecal
bupivacaine alone, without prolonging time for dermatomal regression. Also, Prakash et al.
[35] with Ho and Ismail [64] found that intrathecal midazolam appears to improve perioper‐
ative analgesia and reduce nausea and vomiting during caesarean delivery. On the other hand
in 2011, Shadangi et al. concluded that the addition of preservative-free midazolam to
bupivacaine intrathecally resulted in prolonged postoperative analgesia without increasing
motor block [68].
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Addition of preservative free midazolam to hyperbaric bupivacaine for spinal anesthesia in
different surgical procedures/operations prolongs the duration of effective analgesia as
compared to bupivacaine alone and delays the need for postoperative rescue analgesics
without having any sedative effect, pruritus, or respiratory depression. The use of intrathecal
midazolam also decreases the incidence of postoperative nausea vomiting (PONV). Moreover,
intrathecal midazolam does not have any clinically significant effect on perioperative hemo‐
dynamics. A small diluted dose of preservative-free intrathecal midazolam (<1mg/mL concen‐
tration and 1 to 2.5mg) appears to have few systemic side effects and is free of short-term
neurotoxicity.
4. Sedation in spinal anesthesia with intravenous midazolam
The use of spinal anesthesia is often limited by the unwillingness of patients to remain awake
during surgery [69]. Spinal anesthesia provides anesthesia at the surgical site, yet unpleasant
and uncomfortable patient experiences result from having to remain in the same position,
prolonged duration of surgery or ambient noise in the operating room. To avoid spontaneous
movements by an inadequately sedated patient that can interfere with the surgical procedure,
intravenous sedative medications can be useful in patients who are positioned in specific
postures that can be considered uncomfortable [70]. On the other hand, the goals of sedation
during spinal anesthesia include rapid achievement of adequate sedation, its maintenance at
a constant level during the surgical procedure and awakening the patient quickly at the end.
This can be attained by continuous infusion of sedative drugs preceded by a bolus.
Conscious sedation is a minimally depressed level of consciousness that retains the patient's
ability to maintain his or her airway independently and continuously, and to respond
appropriately to physical stimulation and verbal command, produced by pharmacologic or
non-pharmacologic methods, alone or in combination [71]. With conscious sedation only some
of the centers in the medullary reticular formation and thalamus are depressed in a dose
dependent manner [72]. Thus, this level of sedation provides the additional benefit of preser‐
vation of protective airway reflexes, especially in monitored anesthesia care. An ideal supple‐
mental sedative should provide effective anxiolysis, an easily controllable level of sedation,
predictable depth of amnesia, a rapid and clear headed recovery, minimal intraoperative side
effects, no evidence of cumulation and minimal postoperative side effects. Numerous agents
have been used as sedative adjuvants to spinal anesthesia, each with their own advantages
and disadvantages.
The most widely used technique for administering sedation in regional anesthesia is the
intermittent intravenous bolus dose technique. This technique has been shown to be associated
with peaks and troughs in plasma concentration producing significant side effects and delayed
recovery [73]. Continuous infusions have been proven to produce lesser side effects, faster
recovery, easy controllability over the desired depth of sedation and, should the regional block
prove to be ineffective, easy conversion to general anesthesia [74, 75].
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Of the currently available benzodiazepines, midazolam has a fast onset and short recovery
time, because of which it is one of the most widely used sedatives in spinal anesthesia. With
a low context sensitive half time (70 minutes for a four hour long infusion and up to 100 minutes
for longer infusions), it can be easily titrated to the needs of the patient, making its use well
suited for ambulatory conscious sedation techniques [4, 76]. It produces good sedation and
excellent amnesia but has no specific analgesic properties [77].
Benzodiazepines cause greater depression of upper airway muscle tone in the elderly, resulting
in a higher incidence of airway obstruction [78, 79]. On the other hand, the synergistic effects
between benzodiazepines and other drugs, especially opioids and propofol, facilitate better
sedation and analgesia. However, the combination of these drugs also enhances their respi‐
ratory depression and may lead to airway obstruction or apnea [80]. Administration of oxygen
to all the patients during sedation and immediate relief of airway obstruction prevented the
occurrence of oxygen desaturation. A smaller volume bolus and a slow infusion rate avoided
apnea.
Bolus administration of midazolam 0.05 mg/kg was reported to give enough amnesia and
sedation without any adverse effects on hemodynamics and respiration [80]. With this method,
patients did not respond to verbal command but recovered in 25 minutes [81] and opened their
eyes spontaneously in 47 minutes [82]. As long as patients closed their eyes, amnesic effect
was kept and when they opened their eyes, additional midazolam 1 mg (approximately 18 mcg/
kg) was enough for patient’s comfort [82]. However, bolus administration of sedative can not
provide constant level of sedation. In contrast, continuous infusion can provide constant
sedation level but usually prolongs onset time of sedation compared with the intermittent
bolus technique [83]. Different studies showed that during spinal anesthesia, midazolam (1-2
mg given and followed by 0.1-0.5 mg/kg/hr intravenously) provides rapidly induced sedation and
amnesia with stable hemodynamics and respiration. Oxygen must be administered at 3-6
L/min through a mask during the procedure. Intraoperative monitoring must include electro‐
cardiography, pulse oxmetry, noninvasive sphygmomanometry, and capnography.
Midazolam is considered safe even at high doses and, at equipotent doses, it affects (via
GABA) the central nervous system in a similar fashion [84]. GABA receptors are found in
different parts of the brain. The sedative effects of the benzodiazepines are mediated by the
brainstem GABA receptors that inhibit the ascending pathways that activate the brain cortex.
The ataxia and memory impairment are mediated by GABA receptors in the cerebellar,
hippocampal, and forebrain areas. While hypnosis or sedation is always achieved after
appropriate individually based doses, anxiolysis is seldom transformed into anxiety, restless‐
ness, rage or a myriad of uncontrolled behaviours (midazolam paradox)[84]. The relationship of
the paradoxical reaction to alteration of the cholinergic homeostasis, serotonin levels, the role
of genetics, and gamma-aminobutyric acid receptor configuration are suspect [85]. Such
paradoxical reactions may harm the unconscious or semiconscious patient. Low dose of
flumazenil (0.2-0.3 mg, range 0.1-0.5 mg) completely reverses midazolam-induced paradoxical
reactions and they are more frequent in older patients [84, 85].
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5. Conclusion
Spinal anesthesia has the advantage of being able to maintain spontaneous breathing as well
as relaxing the necessary muscles for surgery. However, the time limit and patient’s anxiety
of spinal anesthesia are important disadvantages. On the other hand, the impediments to the
effective use of spinal anesthesia are the predictable decreases in arterial blood pressure and
heart rate through the accompanying sympathectomy with its attendant vasodilatation and
blockade of cardio accelerator fibres. Another clinically important impediment to successful
block is inadequate sedation. Adjunctive drugs are used to decrease anxiety, alleviate discom‐
fort, improve hemodynamic stability and induce a feeling of calmness during spinal anesthe‐
sia.
When using sedative medication during spinal anesthesia, the anesthesiologist attempts to
titrate the drug to optimize patient comfort while maintaining cardiorespiratory stability and
intact protective reflexes. Morever, adequate sedation in spinal anesthesia relieves the anxiety
of the patient, improves physiological and psychological stress, and increases the satisfaction
of the surgeon, anesthetist and patient. Midazolam is most frequently used as the agent for
sedation. It is often used intravenously in single doses of between 0.5 mg and 2.5 mg. Mida‐
zolam provides rapidly induced sedation and amnesia with stable hemodynamics and
respiration during spinal anesthesia.
Moreover, midazolam has been shown to have antinociceptive effects when administered
intrathecally, both in laboratory animals and in humans. Intrathecal injection up to 2 mg
midazolam have been reported without adverse effects. The paucity of studies on intrathecal
midazolam warrants caution in elderly patients, the obese, and those who are already on other
sedatives. When intrathecal midazolam is used, all patients should be closely monitored intra
and postoperatively. In brief, intrathecal preservative free midazolam appears safe and has
clinically acceptable analgesic properties.
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